CBX3 and neoplasm: NKG2D blockade resulted in uncontrolled tumor growth and decreased survival of treated animals (Figures S6A–D), accompanied by the reduction of Cbx3/HP1γ-deficient CD8+NKG2D+ effector T cells in tumors, to a level similar to PBS-treated control mice (Figures S6E, F).